A total of 1095 patients with operable breast cancer and en-rolled in a randomized clinical trial were analysed for estrogen (ER) and progesterone (PgR) receptor content of their primary tumor, and the relationships between steroid receptor status and several epidemiologic characteristics were studied. The proportion of ER+ and median ER levels increased with age: compared to women younger than 40, those aged 66 or more were approximately three times more likely to have an ER+ tumor (OR = 3.0, 95% C.I. = 1.6–5.7). This difference tended to be more marked after comparison between patients with ER > 100 fmol/mg protein and ER- within the same age groups: OR = 7.04, 95 % C.I. = 2.89–17.12. No association emerged between age and PgR. ER status and concentrations were independent of menopausal status after adjustment for age, whereas the proportion of PgR+ and PgR levels were significantly lower in postmenopausal patients of the same age. The distribution of ER and PgR profiles was similar in relation to family history of breast cancer, reproductive events and other selected epidemiologic characteristics of the patients.
Get full access to this article
View all access options for this article.
References
1.
AllegraJ.C., LippmanM.E., ThompsonE.B., SimonR., BarlockA., GreenL., HuffK.K., DoH.M.T., AitkenS.C.: Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen and glucocorticoid receptors in human breast cancer. Cancer Res., 39: 1447–1454, 1979.
2.
AndryG., SuciuS., PratolaD., SylvesterR., LeclercqG., Menendes da CostaP., LegrosN., Andry-T'HooftM., VerhestA., MattheiemW., HeusonJ-C.: Relation between estrogen receptor concentration and clinical and histological factors: Their relative prognostic importance after radical mastectomy for primary breast cancer. Eur. J. Cancer Clin. Oncol., 25: 319–329, 1989.
3.
BlankensteinM.A.: Comparison of ligand binding assay and enzyme immunoassay of oestrogen receptor in human breast cancer cytosols. Breast Cancer Res. Treat., 17: 91–98, 1990.
4.
BoyleP.: Epidemiology of breast cancer. Baillière's Clin. Oncol., 2: 1–57, 1988.
5.
BrdarB., GrafD., PadovanR., NolaP., RudanN., PetrinecZ., SarcevisB., BeliczaM.: Estrogen and progesterone receptors as prognostic factors in breast cancer. Tumori, 74: 45–52, 1988.
6.
ClarkG.M., McGuireW.L., HubayCA., PearsonO.H., MarshallJ.S.: Progesterone receptors as a prognostic factor in stage II breast cancer. N. Engl. J. Med., 309: 1342–1347, 1983.
7.
ClarkG.M., OsborneC.K., McGuireW.L.: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J. Clin. Oncol., 2: 1102–1109, 1984.
8.
CooperJ.A., RohanT.E., CantE.L.McK., HorsfallD.J., TilleyW.D.: Risk factors for breast cancer by oestrogen receptor status: A population-based case-control study. Br. J. Cancer, 59: 119–125, 1989.
9.
DeSombreE.R., CarboneP.P., JensenE.V., McGuireW.L., WellsS.A.Jr., WittliffJ.L., LipsettM.B.: Steroid receptors in breast cancer. N. Engl. J. Med., 301: 1011–1012, 1979.
10.
ElwoodJ.M., GodolphinW.: Oestrogen receptors in breast tumors: Associations with age, menopausal status and epidemiological and clinical features in 735 patients. Br. J. Cancer, 42: 635–644, 1980.
11.
FisherB., WickerhamD.L., BrownA., RedmondC.K., CunninghamT.J., EvansJ., Legault-PoissonS., PatersonA.H.G., SchipperH.NSABP Investigators: Breast cancer estrogen and progesterone receptor values: Their distribution, degree of concordance, and relation to number of positive axillary nodes. J. Clin. Oncol., 1: 349–358, 1983.
12.
FisherE.R., RedmondC.K., LiuH., RocketteH., FisherB.Collaborating NSABP Investigators: Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer, 45: 349–353, 1980.
13.
G.I.V.I.O.: Oestrogen receptor status and risk factors for breast cancer. Oncology, 45: 303–307, 1988.
14.
HildrethN.G., KelseyJ.L., EisenfelsA.J., Li VolsiV.A., HolfordT.R., FischerD.B.: Differences in breast cancer risk factors according to the estrogen receptor level of the tumor. J. Natl. Cancer Inst., 70: 1027–1031, 1983.
15.
HulkaB.S., ChamblessL.E., WilkinsonW.E., DeubnerD.C., McCartyK.S., McCartyK.S.Jr.: Hormonal and personal effects on estrogen receptors in breast cancer. Am. J. Epidemiol., 119: 692–704, 1984.
16.
KinneD.W., AshikariR., ButlerA., Menedez-BotetC., RosenP.P., SchwartzM.: Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer, 47: 2364–2367, 1981.
17.
KoendersA., ThorpeS.M.: Standardization of steroid receptor assay in human breast cancer. I. Reproducibility of estradiol and progesterone receptor assay. Eur. J. Cancer Clin. Oncol., 19: 1221–1229, 1983.
18.
LeavittW.W., ToftD.O., StrottC.A.: A specific progesterone receptor in the hamster uterus: Physiologic properties and regulation during the estrous cycle. Endocrinology, 94: 1041–1053, 1974.
19.
LesserM.L., RosenP.P., SenieR.T., DuthieK., Menendez-BotetC., SchwartzM.K.: Estrogen and progesterone receptors in breast carcinoma: Correlations with epidemiology and pathology. Cancer, 48: 299–309, 1981.
20.
LiberatiA., Rosselli Del TurcoM., CiattoS., FossatiR.: Follow-up in breast cancer (letter). JAMA, 265: 2669, 1991.
21.
MantelN.: Chi-square tests with one degree of freedom, extensions of the Mantel-Haenszel procedure. J. Am. Stat. Assoc, 58: 690–700, 1963.
22.
MarchettiE., QuerzoliP., MoncharmontB., ParikhL., BagniA., MarzolaA., FabrisG., NenciI.: Immunocytochemical demonstration of estrogen receptors by monoclonal antibodies in human breast cancer: correlation with estrogen receptor assay by dextran coated charcoal method. Cancer Res., 47: 2508–2513, 1987.
23.
McGuireW.L., ClarkG.M.: The prognostic role of progesterone receptors in human breast cancer. Semin. Oncol., 10(suppl. 4): 2–6, 1983.
24.
McTiernanA., ThomasD.B., JohnsonL.K., RosemanD.: Risk factors for estrogen receptor-rich and estrogen receptor-poor breast cancers. J. Natl. Cancer Inst., 77: 849–854, 1986.
25.
MontescoM.C., PluchinottaA., PiffanelliA., PelizzolaD., GiovanniniG., Arslan PagniniG.: Hormone receptors and breast cancer: Correlations with clinical and histological features. Tumori, 70: 445–450, 1984.
26.
NomuraY., TashiroH., HamadaY., ShigematsuT.: Relationship between estrogen receptors and risk factors of breast cancer in Japanese pre- and postmenopausal patients. Breast Cancer Res. Treat., 4: 37–43, 1984.
27.
OsborneC.K., YochmowitzM.G., KnightW.A.III, McGuireW.L.: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer, 46: 2884–2888, 1980.
28.
PiffanelliA., PelizzolaD., De BortoliM., AgrimontiF., FrairiaR., GiovanniniG., FumeroS.: Quality assurance for steroid receptor assay in human breast cancer: Six years experience of the Italian Committee. Tumori, 71: 589–595, 1985.
29.
PiffanelliA., PelizzolaD., De BortoliM., GiovanniniG., MesseriG., QuercioliM., FumeroS.: Dosaggio radiometrico dei recettori steroidei nel cancro mammario. Biochem. Clin., 11: 38–46, 1987.
30.
RothG.S., HessG.D.: Changes in the mechanism of hormone and neurotransmitter action during aging: Current status of the role of receptor and post-receptor alterations. A review. Mech. Ageing Dev., 20: 175–194, 1982.
31.
RuderA.M., LubinF., WaxY., GeierA., AlfundaryE., ChetritA.: Estrogen and progesterone receptors in breast cancer patients. Epidemiologic characteristics and survival differences. Cancer, 64: 196–202, 1989.
32.
StanfordJ.L., SzkloM., BrintonL.A.: Estrogen receptors and breast cancer. Epidemiol. Rev., 8: 42–59, 1986.
33.
StandfordJ.L., SzkloM., BoringC.C., BrintonL.A., DiamondE.A., GreenbergR.S., HooverR.N.: A case-control study of breast cancer stratified by estrogen receptor status. Am. J. Epidemiol., 125: 184–194, 1987.
34.
ThorpeS.M., RoseC., PedersenB.V., Bruun RasmussenB.: Estrogen and progesterone receptor profile patterns in primary breast cancer. Breast Cancer Res. Treat., 3: 103–110, 1983.
